Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00FCV
|
||||
| Former ID |
DIB013975
|
||||
| Drug Name |
Inhaled liposomal ciprofloxacin
|
||||
| Indication | Cystic fibrosis [ICD9: 277; ICD10:E84] | Phase 2 | [1] | ||
| Company |
Aradigm
|
||||
| Target and Pathway | |||||
| Target(s) | Topoisomerase IV subunit A | Target Info | Modulator | [2] | |
| DNA gyraseA subunit | Target Info | Modulator | [2] | ||
| References | |||||
| REF 1 | Inhaled Ciprofloxacin for the Management of Infections in Non-Cystic Fibrosis Bronchiectasis (BE) Patients | ||||
| REF 2 | Selective Targeting of Topoisomerase IV and DNA Gyrase in Staphylococcus aureus: Different Patterns of Quinolone- Induced Inhibition of DNA Synthesis. Antimicrob Agents Chemother. 2000 August; 44(8):2160-2165. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.